Kerendia
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Kerendia
- Generic name
- FINERENONE
- Manufacturer
- Bayer HealthCare Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- fc726765-5d5a-4d6e-b037-b847bda9fb7c
- SPL ID
- 0be3a1c5-0088-43b1-b2f0-1faa1ea87c5b
- Version
- 15
- Effective date
- 2026-09-21
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:38
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 215341 | derived:openfda.application_number |
| application number | NDA215341 | openfda.application_number | |
| brand name | Kerendia | openfda.brand_name | |
| generic name | FINERENONE | openfda.generic_name | |
| manufacturer name | Bayer HealthCare Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 50419-540-01 | openfda.package_ndc |
| ndc | package | 50419-542-01 | openfda.package_ndc |
| ndc | package | 50419-540-70 | openfda.package_ndc |
| ndc | package | 50419-541-02 | openfda.package_ndc |
| ndc | package | 50419-540-02 | openfda.package_ndc |
| ndc | package | 50419-542-02 | openfda.package_ndc |
| ndc | package | 50419-541-01 | openfda.package_ndc |
| ndc | package | 50419-541-06 | openfda.package_ndc |
| ndc | package | 50419-542-70 | openfda.package_ndc |
| ndc | package | 50419-541-70 | openfda.package_ndc |
| ndc | package | 50419-542-06 | openfda.package_ndc |
| ndc | package | 50419-540-06 | openfda.package_ndc |
| ndc | product | 50419-540 | openfda.product_ndc |
| ndc | product | 50419-541 | openfda.product_ndc |
| ndc | product | 50419-542 | openfda.product_ndc |
| ndc11 | package | 50419054001 | derived:openfda.package_ndc |
| ndc11 | package | 50419054106 | derived:openfda.package_ndc |
| ndc11 | package | 50419054101 | derived:openfda.package_ndc |
| ndc11 | package | 50419054070 | derived:openfda.package_ndc |
| ndc11 | package | 50419054202 | derived:openfda.package_ndc |
| ndc11 | package | 50419054002 | derived:openfda.package_ndc |
| ndc11 | package | 50419054206 | derived:openfda.package_ndc |
| ndc11 | package | 50419054006 | derived:openfda.package_ndc |
| ndc11 | package | 50419054201 | derived:openfda.package_ndc |
| ndc11 | package | 50419054102 | derived:openfda.package_ndc |
| ndc11 | package | 50419054270 | derived:openfda.package_ndc |
| ndc11 | package | 50419054170 | derived:openfda.package_ndc |
| rxcui | 2562816 | openfda.rxcui | |
| rxcui | 2562822 | openfda.rxcui | |
| rxcui | 2720069 | openfda.rxcui | |
| rxcui | 2562824 | openfda.rxcui | |
| rxcui | 2720071 | openfda.rxcui | |
| rxcui | 2562826 | openfda.rxcui | |
| spl id | 0be3a1c5-0088-43b1-b2f0-1faa1ea87c5b | id | |
| spl set id | fc726765-5d5a-4d6e-b037-b847bda9fb7c | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hyperkalemia. Patients with decreased kidney function and higher baseline potassium levels are at increased risk. Monitor serum potassium levels and adjust dose as needed. ( 2.1 , 2.2 , 2.3 , 5.1 ) Worsening of Renal Function in Patients with Heart Failure. Measure eGFR and adjust dose as needed. ( 2.1 , 2.3 , 6.1 ) 5.1 Hyperkalemia Kerendia can cause hyperkalemia [see Adverse Reactions (6.1) ] . The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with Kerendia and dose accordingly [see Dosage and Administration (2.1) ] . Do not initiate Kerendia if serum potassium is > 5.0 mEq/L. Measure serum potassium periodically during treatment with Kerendia and adjust dose accordingly [see Dosage and Administration (2.3) ] . More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium [see Drug Interactions (7.1 , 7.2) ] . 5.2 Worsening of Renal Function in Patients with Heart Failure Kerendia can cause worsening of renal function in patients with heart failure. Rarely, severe events associated with worsening renal function, including events requiring hospitalization, have been observed [see Adverse Reactions (6.1) ] . Measure eGFR in all patients before initiation of treatment or with dose titration of Kerendia and dose accordingly [see Dosage and Administration (2.1 , 2.3) ]. Initiation of Kerendia in patients with heart failure and an eGFR <25 mL/min/1.73m 2 is not recommended. Measure eGFR periodically during maintenance treatment with Kerendia in patients with heart failure. Consider delaying up-titration or interrupting treatment with Kerendia in patients who develop clinically significant worsening of renal function.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Hyperkalemia [see Warnings and Precautions (5.1) ] Adverse reactions occurring in ≥ 1% of patients on Kerendia and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. CKD associated with T2DM The safety of Kerendia in patients with CKD associated with T2DM was evaluated in 2 randomized, double-blind, placebo-controlled, multicenter pivotal phase 3 studies, FIDELIO-DKD and FIGARO-DKD, in which a total of 6510 patients were treated with 10 or 20 mg once daily over a mean duration of 2.2 and 2.9 years, respectively. Overall, serious adverse events occurred in 32% of patients receiving Kerendia and in 34% of patients receiving placebo in the FIDELIO-DKD study; the findings were similar in the FIGARO-DKD study. Permanent discontinuations due to adverse events also occurred in a similar proportion of patients in the two studies (6-7% of patients receiving Kerendia and in 5-6% of patients receiving placebo). The most frequently reported (≥ 10%) adverse reaction was hyperkalemia [see Warnings and Precautions (5.1) ]. Hospitalization due to hyperkalemia for the Kerendia group was 0.9% vs 0.2% in the placebo group across both studies. Hyperkalemia led to permanent discontinuation of treatment in 1.7% receiving Kerendia versus 0.6% of patients receiving placebo across both studies. Table 4 shows adverse reactions that occurred more commonly on Kerendia than on placebo, and in at least 1% of patients treated with Kerendia. Table 4: Adverse reactions reported in ≥ 1% of patients on Kerendia and more frequently than placebo (Pooled data from FIDELIO-DKD and FIGARO-DKD) Adverse reactions Kerendia N=6510 n (%) Placebo N=6489 n (%) Hyperkalemia 912 (14.0) 448 (6.9) Hypotension 302 (4.6) 194 (3.0) Hyponatremia 82 (1.3) 47 (0.7) CKD associated with T1DM The safety of Kerendia in patients with CKD associated with T1DM was evaluated in the randomized, double-blind, placebo-controlled, multicenter pivotal phase 3 study, FINE-ONE. In this study, 119 patients received Kerendia (10 mg or 20 mg) once daily over a mean duration of treatment of 5.9 months. The overall safety profile of Kerendia in the FINE-ONE study was consistent with the adverse reactions reported in patients with CKD associated with T2DM (Table 4). Heart Failure with LVEF ≥ 40% The safety of Kerendia in patients with heart failure (LVEF ≥ 40%) was evaluated in the randomized, double-blind, placebo-controlled, multicenter pivotal phase 3 study, FINEARTS-HF, in which a total of 2,993 patients were treated with 10 mg, 20 mg, or 40 mg once daily of Kerendia with a mean duration of treatment of 2.3 years. The overall safety profile of Kerendia in the FINEARTS-HF study was largely consistent with the adverse reactions reported in patients with CKD and T2DM (Table 4). However, adverse reactions related to worsening renal function were reported more frequently in the Kerendia group (18%) compared with placebo (12%) in FINEARTS-HF. The most frequently reported adverse reactions included renal impairment (7% vs. 4%), eGFR decreased (5% vs. 4%), acute kidney injury (4% vs. 2%) and renal failure (3% vs. 2%). The majority of events were reported to be mild to moderate. These events led to dose modifications in 9% of patients receiving Kerendia versus 4% of patients receiving placebo. Hospitalization due to events related to worsening of renal function for the Kerendia group was 2.0% versus 1.3% in the placebo group. Laboratory Test Initiation of Kerendia may cause an initial small increase in blood creatinine levels (mean change <0.1 mg/dL) and a small decrease in eGFR (mean change 2-3 mL/min) that occurs within the first 4 weeks of starting therapy and then stabilizes. These changes were reversible after treatment discontinuation. Initiation of Kerendia may also cause a small increase in serum uric acid. This increase appears to attenuate over time. 6.2 Postmarketing Experience The following additional adverse reactions have been reported in postmarketing experience with finerenone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure: Hypersensitivity: Angioedema, Rash and Urticaria
adverse reactions table
<table ID="table4" width="90%"> <caption>Table 4: Adverse reactions reported in ≥ 1% of patients on Kerendia and more frequently than placebo (Pooled data from FIDELIO-DKD and FIGARO-DKD)</caption> <col width="40%" align="left" valign="middle"/> <col width="30%" align="center" valign="middle"/> <col width="30%" align="center" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule" align="center">Adverse reactions</th> <th styleCode="Rrule">Kerendia N=6510 n (%)</th> <th styleCode="Rrule">Placebo N=6489 n (%)</th> </tr> </thead> <tbody> <tr styleCode="botrule"> <td styleCode="Lrule Rrule">Hyperkalemia</td> <td styleCode="Rrule">912 (14.0)</td> <td styleCode="Rrule">448 (6.9)</td> </tr> <tr styleCode="botrule"> <td styleCode="Lrule Rrule">Hypotension</td> <td styleCode="Rrule">302 (4.6)</td> <td styleCode="Rrule">194 (3.0)</td> </tr> <tr> <td styleCode="Lrule Rrule">Hyponatremia</td> <td styleCode="Rrule">82 (1.3)</td> <td styleCode="Rrule">47 (0.7)</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.